Accelerated hyperfractionation radiation therapy after lumpectomy and axillary lymph node dissection in patients with stage I or II breast cancer: pilot study.
Accelerated hyperfractionation radiation therapy after lumpectomy and axillary lymph node dissection in patients with stage I or II breast cancer: pilot study.
复制标题
I 期或 II 期乳腺癌患者在肿瘤切除术和腋窝淋巴结清扫术后加速超分割放射治疗：初步研究。
DOI：
10.1148/radiology.202.2.9015091
复制
发表时间：
1997
期刊：
影响因子：
--
通讯作者：
Pisansky,TM
中科院分区：
文献类型：
--
作者：
Schomberg,PJ;Shanahan,TG;Ingle,JN;Donohue,JH;Kuske,RR;Sternfeld,WC;Wold,L;Cha,SS;Petersen,IA;Brindle,JS;Halyard,MY;Bollinger,JW;Hawkins,R;Pisansky,TM
前瞻性地评估接受保乳治疗的患者对加速超分割放射治疗的耐受性，并以90%的置信度排除20%或更大的急性毒性反应至少3级(严重)的风险。材料和方法：7名患者(年龄33-80岁)在可评估的病例中，乳房和区域淋巴结(如果累及三个或更多淋巴结)接受每日两次的1.6Gy48 Gy射线照射，每天两次增加9.6Gy.6Gy.根据放射治疗肿瘤学小组和欧洲癌症研究和治疗组织的放射发病率标准对急性和晚期反应进行评分。结果1例患者出现3级急性皮肤毒性反应，另1例出现3级(持续性)急性水肿症。目前尚无4级(危及生命)急性毒性反应、局部复发或与癌症或治疗相关的死亡。额外的随访是必要的，以确定长期发病率和美容，有必要在更大的患者组中进行进一步研究，以确认疗效。
PURPOSETo prospectively assess tolerance to accelerated hyperfractionation radiation therapy in patients undergoing breast-conservation therapy and to exclude, with 90% confidence, a 20% or greater risk of an acute toxic reaction of at least grade 3 (severe).MATERIALS AND METHODSThirty-seven patients (aged 33-80 years) with evaluatable cases received 48 Gy in twice-daily 1.6-Gy fractions to the breast and regional lymph nodes (if three or more lymph nodes were involved) and a boost of 9.6 Gy in twice-daily 1.6-Gy fractions. Acute and late effects were scored by using the Radiation Therapy Oncology Group and European Organization for the Research and Treatment of Cancer radiation morbidity criteria.RESULTSOne patient developed a grade 3 acute skin toxic reaction and another grade 3 (continuous) acute edema. There have been no grade 4 (life-threatening) acute toxic reactions, local recurrences, or cancer- or treatment-related deaths.CONCLUSIONThis breast-conservation accelerated hyperfractionation radiation therapy schedule is tolerable. Additional follow-up is necessary to determine long-term morbidity and cosmesis, and further study in a larger patient group is necessary to confirm efficacy.